@article{c0adec3b5ad54b5facbe36c851bb41c7,
title = "A mouse pancreatic organoid model to compare PD-L1 blocking antibodies",
abstract = "Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape for cancer patients, but diabetes, a rare, severe immune-related endocrinopathy, is linked to ICI therapy. It is unclear whether glycosylation of ICIs may play a role in the development of this adverse event and how the physiological effects of different ICIs on pancreatic cells should be evaluated. We used a mouse pancreatic organoid model to compare three PD-L1 blocking antibodies in the presence or absence of IFNγ using a metabolic bioanalyzer. Modulation of ICI glycosylation altered its metabolic effects on mouse pancreatic organoids, suggesting that this model could be used to monitor and compare ICIs and to study the mechanisms underlying the development of IC-mediated diabetes.",
keywords = "Immune checkpoint inhibitors, PD-L1, diabetes, metabolism, pancreatic organoids",
author = "Guangyuan Li and Susmita Ghosh and Park, {Ju Me} and Hyunsu Shin and Mamatha Garige and Gregory Reaman and Carole Sourbier",
note = "Funding Information: We thank Dr Michael Moses and Dr Nozomi Sakakibara (FDA) for helpful discussions. G.L., S.G., and JM.P. were fellows in the Research Participation Program at the Center for Drug Evaluation and Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. H.S. was supported by the NCI/FDA Interagency Oncology Task Force (IOTF) Fellowship program. Funding Information: His research was supported by FDA intramural research funding. U.S. Food and Drug Administration. We thank Dr Michael Moses and Dr Nozomi Sakakibara (FDA) for helpful discussions. G.L., S.G., and JM.P. were fellows in the Research Participation Program at the Center for Drug Evaluation and Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. H.S. was supported by the NCI/FDA Interagency Oncology Task Force (IOTF) Fellowship program. Publisher Copyright: {\textcopyright} This work was authored as part of the Contributor{\textquoteright}s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC 105, no copyright protection is available for such works under US Law.",
year = "2022",
month = jan,
day = "1",
doi = "10.1080/19420862.2022.2139886",
language = "English",
volume = "14",
journal = "mAbs",
issn = "1942-0862",
publisher = "Landes Bioscience",
number = "1",
}
